First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.
7/2/26
MOREPEN LABORATORIES (MOREPENLAB.NS)
Thursday
9:26 AM
Thesis: Morepen Laboratories: the story is balanced — API pricing trends for key molecules (atorvastatin, metformin, losartan) - spot price volatility in China-sourced…
value - The stock trades at 1.2x P/S and 1.8x P/B with 22.7% net income growth…
Moderate sensitivity through two channels: (1) The company's capex program ($1.2B TTM) likely involves project financing…
Watch on earnings: China API price indices (atorvastatin, metformin bulk prices) - leading indicator for Morepen's input costs and competitive pricing pressure, US FDA inspection calendar and warning letter database - regulatory risk events that can halt exports, Indian rupee vs USD exchange rate (USDINR) - 100 basis point depreciation adds ~40-50 bps to EBITDA margin on export sales.
One Sentence Summary:
Morepen Laboratories: the story is balanced — api pricing trends for key molecules (atorvastatin, metformin, losartan) - spot price volatility in china-sourced intermediates directly.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.